Science to Secure
Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.
Aerium Therapeutics is developing medicines to protect the world against pandemic and epidemic threats.
Aerium’s current focus is on the protection of immunocompromised persons, who account for approximately 3-6% of the adult population in the US. These individuals’ immune systems may not respond fully to vaccination, leaving them vulnerable to COVID-19 and severe outcomes of the disease. Our lead program is a combination of two long-acting monoclonal antibodies against SARS-CoV-2 that have potent activity against all major variants identified to date and present a high barrier to future virus evasion.
Aerium is also collaborating with the University of California, San Francisco to evaluate an anti-SARS-CoV-2 antibody for the treatment of Long COVID, which is estimated to affect up to 18 million persons in the US alone.
Aerium’s fully integrated discovery platform is derived from a broad network of international experts and research infrastructure at leading medical institutions. Capabilities include a BSL-3/P3 laboratory for advanced viral assays, Cryo-EM expertise for rapid viral protein characterization, and an active antibody discovery platform, which support our lead program and enable further expansion of our pipeline.